Search the site for any medical term or simply browse by disease topic. Access all the information you need in one place, when you need it, how you want it and for free!
Launch of accredited Type 1 Childhood Diabetes CME
A new EACCME-accredited CME activity Individual Patient Management in Type 1 Childhood Diabetes has launched on epgonline.org. Intended for medical professionals involved in the management of young patients with type 1 diabetes, this module consists of six sessions, each covering a different aspect of managing psychosocial issues in type 1 childhood diabetes.
Explore at your own pace and test your knowledge using the interactive learning exercises. The activity is totally free, and on completion you will be awarded 1 European CME credit (ECMEC).
Anti-Infectives Knowledge Network (AIKN) CDI Updates
Recently updated with new reports and policy updates as well as key perspectives on Clostridium difficile infection (CDI), the Anti-Infectives Knowledge Network shares expertise and experience in the area of anti-infectives.
This educational resource is an initiative by Astellas Pharma EMEA. Please remember to return often to read the news, clinical insights, and essential information from the latest anti-infective congresses.
January 2015 FDX/15/0003/EU
This free CME activity covers the best practice management of nocturnal enuresis through three case study-led modules, including a more severe and complex patient scenario. It is intended for Urologists, Paediatricians, Primary Care Providers and General Practitioners looking to improve their understanding and management of bedwetting.
Accredited Obesity CME
The EACCME accredited European Obesity Initiative eCME module – Understanding Obesity, is freely accessible to healthcare professionals. Upon successful completion, participants will be awarded 2 European CME credits (ECMECs) and have a broad understanding of the epidemiology, contributory factors and management options for patients with obesity.
Type 2 Diabetes accredited CME
‘Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin’ is EACCME accredited and awarded 1 European CME credit (ECMEC). There are 3 modules:
- A Review of Newer Therapies for Type 2 Diabetes in Combination with Insulin; John Wilding (Chair)
- Identifying and Managing the Psychosocial Aspects of Type 2 Diabetes Mellitus; Richard Holt (Faculty)
- Potential Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin: Interactive Case Discussion; Bernard Charbonnel (Faculty)
Sorin S.p.A. a global medical device company and a leader in the treatment of cardiovascular diseases, and Cyberonics Inc. a medical device company with core expertise in neuromodulation, announced their merger plan to create a new global leader in ...
Actavis plc confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the FDA seeking approval to market Budesonide Extended-release Tablets, 9 mg. Actavis' ANDA product is a generic version of Salix Pharmaceuticals' Uceris, ...
Actavis plc announced the FDA has approved Avycaz (ceftazidime-avibactam). Avycaz was approved for the treatment of adult patients with complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract ...
Eli Lilly and Company announced a delay in the submission of basal insulin peglispro (BIL) (LY 2605541) to regulatory agencies beyond the first quarter of 2015. The delay includes filings with the FDA and the European Medicines Agency. Lilly will ...
Shire plca nd Meritage Pharma, Inc. announced that Shire has acquired Meritage, a privately-held company, for an upfront fee of $70 million and additional contingent payments based on the achievement of development and regulatory milestones. With the ...
A new EACCME-accredited CME activity Individual Patient Management in Type 1 Childhood Diabetes has launched on epgonline.org. This activity is intended for an audience of medical professionals involved in the management of patients with type 1 ...
Celsion Corporation has announced updated results from its retrospective analysis of the Company's 701-patient HEAT Study of ThermoDox (heat-activated liposomal doxorubicin), in combination with radiofrequency ablation (RFA) in primary liver ...